Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,928

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)

BIOLOGICAL

VCIV manufactured with the current manufacturing process (VCIV current)

BIOLOGICAL

Fluzone®, licensed trivalent influenza vaccine (TIV)

Trial Locations (20)

14609

Rochester Clinical Research Inc., Rochester

27518

PMG Research of Cary, LLC, Cary

27612

Wake Research Associates, LLC, Raleigh

29303

Spartanburg Medical Research, Spartanburg

30281

Clinical Research Atlanta, Stockbridge

32720

Avail Clinical Research, LLC, DeLand

33134

Clinical Research of South Florida, Coral Gables

33143

Miami Research Associates, South Miami

44122

Rapid Medical Research, Inc., Cleveland

63141

Sundance Clinical Research, LLC, St Louis

64114

The Center for Pharmaceutical Research, P.C., Kansas City

67207

Heartland Research Associates, LLC, Wichita

76135

Benchmark Research, Fort Worth

78705

Benchmark Research Austin, Austin

84124

Jean Brown Research, Salt Lake City

85224

East Valley Family Physicians, PLC, Chandler

90723

Center for Clinical Trials, LLC, Paramount

92103

California Research Foundation, San Diego

92801

Anaheim Clinical Trials, Anaheim

94102

Benchmark Research San Francisco, San Francisco

All Listed Sponsors
lead

Alachua Government Services, Inc.

INDUSTRY

NCT01773928 - Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) | Biotech Hunter | Biotech Hunter